<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 25-year-old female with achondroplastic <z:hpo ids='HP_0003510'>dwarfism</z:hpo>, diagnosed when she was six months old, was diagnosed with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase with 9;22 translocation, A2B3 gene rearrangement and a Sokal index of 0.5 </plain></SENT>
<SENT sid="1" pm="."><plain>A recombinant interferon-alpha 2A treatment was started in October '94, which obtained a hematological, but not a karyotypic, response at the 6th and 12th month </plain></SENT>
<SENT sid="2" pm="."><plain>In August '94, the patient was submitted to allogeneic bone marrow transplantation (alloBMT) from a 36-year-old matched sibling </plain></SENT>
<SENT sid="3" pm="."><plain>The procedure was well tolerated </plain></SENT>
<SENT sid="4" pm="."><plain>Disease-free survival (DFS) and overall survival (OS) were 21 and 39 months, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>We have not found any reported cases of achondroplastic patients submitted to alloBMT in the literature or in the IBMT Registry </plain></SENT>
</text></document>